| Literature DB >> 36178688 |
Christine T Cigolle1,2,3, Caroline S Blaum4, Chen Lyu5, Jinkyung Ha2, Mohammed Kabeto2, Judy Zhong5.
Abstract
Importance: Older adults vary widely in age at diagnosis and duration of type 2 diabetes, but treatment often ignores this heterogeneity.Entities:
Mesh:
Year: 2022 PMID: 36178688 PMCID: PMC9526092 DOI: 10.1001/jamanetworkopen.2022.32766
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Figure 1. Flowchart of the Study Design
HRS indicates Health and Retirement Study.
aFor each outcome, we further excluded individuals with missing outcomes or with an outcome before diabetes diagnosis. The sample size for each outcome is listed in eTable 2 in the Supplement.
bMatched 1:1 by propensity score constructed by HRS birth cohort, sex, race and ethnicity, educational attainment, calendar year of diabetes diagnosis, age, marital status, wealth, body mass index, activities of daily living and instrumental activities of daily living score, cognitive status, and comorbid conditions during the calendar year of diabetes diagnosis. Matched controls were only identified for individuals with diabetes with complete covariates during the calendar year of diabetes diagnosis. The sample sizes of the individuals with diabetes and complete covariates and the matched controls are listed in eTable 2 in the Supplement for each outcome.
Characteristics of HRS Respondents With Diabetes by Age at Diagnosis and Overall
| Characteristics | Age-at-diagnosis group | ||||
|---|---|---|---|---|---|
| Overall (N = 7739) | 50-59 y (n = 1866) | 60-69 y (n = 2834) | ≥70 y (n = 3039) | ||
| Sex | |||||
| Women | 4267 (55.1) | 1145 (61.4) | 1466 (51.7) | 1656 (54.5) | <.001 |
| Men | 3472 (44.9) | 721 (38.6) | 1368 (48.3) | 1383 (45.5) | |
| Race and ethnicity | |||||
| Hispanic | 726 (9.4) | 272 (14.6) | 279 (9.9) | 175 (5.8) | <.001 |
| Non-Hispanic Black | 1730 (22.4) | 521 (28.0) | 674 (23.8) | 535 (17.6) | |
| Non-Hispanic White | 4891 (63.3) | 930 (49.9) | 1721 (60.9) | 2240 (73.7) | |
| Other | 383 (5.0) | 140 (7.5) | 154 (5.4) | 89 (2.9) | |
| Educational attainment, y | |||||
| <12 | 2682 (34.8) | 550 (29.6) | 932 (33.0) | 1200 (39.5) | <.001 |
| 12 | 2425 (31.4) | 568 (30.6) | 885 (31.3) | 972 (32.0) | |
| >12 | 2610 (33.8) | 737 (39.7) | 1006 (35.6) | 867 (28.5) | |
| Cohort | |||||
| AHEAD | 1394 (18.0) | 0 | 0 | 1394 (45.9) | <.001 |
| CODA | 765 (9.9) | 0 | 176 (6.2) | 589 (19.4) | |
| HRS (refers to original HRS cohort) | 2960 (38.2) | 521 (27.9) | 1536 (54.2) | 903 (29.7) | |
| WB | 850 (11.0) | 311 (16.7) | 399 (14.1) | 140 (4.6) | |
| BB | 1770 (22.9) | 1034 (55.4) | 723 (25.5) | 13 (0.4) | |
| Age at diagnosis, mean (SD), y | 67.4 (9.9) | 55.5 (2.8) | 64.2 (2.8) | 77.7 (5.8) | <.001 |
| Not married or living alone | 2805 (36.2) | 490 (26.3) | 882 (31.1) | 1433 (47.1) | <.001 |
| Wealth, $ | |||||
| <40 000 | 4963 (64.1) | 981 (52.6) | 1696 (59.8) | 2286 (75.2) | <.001 |
| 40 000-149 999 | 2420 (31.3) | 772 (41.4) | 991 (35.0) | 657 (21.6) | |
| 150 000-299 999 | 280 (3.6) | 93 (5.0) | 113 (4.0) | 74 (2.4) | |
| ≥300 000 | 76 (1.0) | 20 (1.1) | 34 (1.2) | 22 (0.7) | |
| BMI, median (IQR) | 29.1 (25.7-33.0) | 31.3 (27.4-35.9) | 30.1 (27.1-34.0) | 27.4 (24.3-30.9) | <.001 |
| Current smoker | 969 (12.5) | 372 (19.9) | 404 (14.3) | 193 (6.4) | <.001 |
| Comorbidity | |||||
| Heart disease | 2584 (33.4) | 387 (20.7) | 847 (29.9) | 1350 (44.4) | <.001 |
| Stroke | 901 (11.6) | 125 (6.7) | 260 (9.2) | 516 (17.0) | <.001 |
| Lung disease | 1012 (13.1) | 217 (11.6) | 372 (13.1) | 423 (13.9) | .07 |
| Cancer | 1076 (13.9) | 129 (6.9) | 334 (11.8) | 613 (20.2) | <.001 |
| Arthritis | 4851 (62.7) | 945 (50.6) | 1833 (64.7) | 2073 (68.2) | <.001 |
| Disability | 375 (4.8) | 36 (1.9) | 72 (2.5) | 267 (8.8) | <.001 |
| Cognitive impairment | |||||
| Normal | 5579 (72.1) | 1550 (83.1) | 2209 (77.9) | 1820 (59.9) | <.001 |
| Minor impairment | 1454 (18.8) | 264 (14.1) | 476 (16.8) | 714 (23.5) | |
| Severe impairment | 706 (9.1) | 52 (2.8) | 149 (5.3) | 505 (16.6) | |
| During follow-up | |||||
| Insulin use | 2183 (28.2) | 701 (37.6) | 773 (27.3) | 709 (23.3) | <.001 |
| Oral medication for diabetes | 6209 (80.2) | 1521 (81.5) | 2361 (83.3) | 2327 (76.6) | <.001 |
| Death | 3555 (45.9) | 507 (27.2) | 1093 (38.6) | 1955 (64.3) | <.001 |
| Follow-up, median (IQR), y | 20 (8-26) | 12 (8-20) | 20 (12-26) | 25 (20-26) | <.001 |
Abbreviations: AHEAD, Assets and Health Dynamics Among the Oldest Old; BB, Baby Boomer (combination of Early and Middle Baby Boomers); BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CODA, Children of the Depression; HRS, the Health and Retirement Study; WB, War Baby.
Unless indicated otherwise, data are expressed as No. (%) of participants. Percentages have been rounded and may not total 100. Owing to missing data, some numbers of participants may be less than the totals given in the column headings.
P values are from ANOVA or rank sum test (for BMI) for comparing continuous covariates and the χ2 test for comparing categorical covariates.
Includes American Indian or Alaska Native, Asian, and Native Hawaiian or other Pacific Islander.
Includes 6 birth cohorts: the AHEAD cohort (individuals born before 1924), the CODA cohort (individuals born between 1924 and 1930), the original HRS cohort (individuals born between 1931 and 1941), the WB cohort (individuals born between 1942 and 1947), the Early Baby Boomer cohort (individuals born between 1948 and 1953), and the Middle Baby Boomer cohort (individuals born between 1954 and 1959).
Figure 2. Incidence of Distal Outcomes for Each Age-at-Diagnosis Group With Diabetes and Its Matched Control (MC) Group
Incidence per 1000 person-years is listed for heart disease, stroke, disability (activities of daily living and instrumental activities of daily living score >5), severe cognitive impairment, and all-cause mortality for each age-at-diagnosis group with diabetes and its MC group. Incidence rate ratios (IRRs) between participants with diabetes and the MCs for each outcome are estimated for each age-at-diagnosis group separately.
Figure 3. Cumulative Incidence Curves of Distal Outcomes for Each Age-at-Diagnosis Group With Diabetes and Its Matched Control (MC) Group
Disability is indicated by activities of daily living and instrumental activities of daily living score of greater than 5. The x-axis of each figure is the duration of diabetes for participants with diabetes and aging for the MCs. The starting point of the follow-up years is the year of diabetes diagnosis for participants with diabetes and the matched calendar year for the MCs.
Figure 4. Hazard Ratios (HRs) of Diabetes on Distal Outcomes Compared With Matched Controls (MCs) by Diabetes Age-at-Diagnosis Groups
The HRs between diabetes age-at-diagnosis and MC groups are estimated for each outcome. The P value column tests the corresponding HR of diabetes to the null hypothesis (HR of 1.00). The interaction P value column compares the HR of diabetes of the corresponding age-at-diagnosis group with the HR of diabetes in the reference group with age at diagnosis at 50 to 59 years.